- Home
- CECO vs ANAB Comparison
CECO vs ANAB Comparison
Compare CECO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CECO
- ANAB
- Stock Information
- Founded
- CECO 1966
- ANAB 2005
- Country
- CECO United States
- ANAB United States
- Employees
- CECO N/A
- ANAB N/A
- Industry
- CECO Pollution Control Equipment
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- CECO Industrials
- ANAB Health Care
- Exchange
- CECO Nasdaq
- ANAB Nasdaq
- Market Cap
- CECO 889.5M
- ANAB 759.5M
- IPO Year
- CECO N/A
- ANAB 2017
- Fundamental
- Price
- CECO $23.00
- ANAB $18.59
- Analyst Decision
- CECO Strong Buy
- ANAB Buy
- Analyst Count
- CECO 5
- ANAB 12
- Target Price
- CECO $36.50
- ANAB $41.20
- AVG Volume (30 Days)
- CECO 213.5K
- ANAB 1.4M
- Earning Date
- CECO 02-25-2025
- ANAB 03-10-2025
- Dividend Yield
- CECO N/A
- ANAB N/A
- EPS Growth
- CECO N/A
- ANAB N/A
- EPS
- CECO 0.33
- ANAB N/A
- Revenue
- CECO $553,078,000.00
- ANAB $57,172,000.00
- Revenue This Year
- CECO $4.67
- ANAB $229.13
- Revenue Next Year
- CECO $24.49
- ANAB N/A
- P/E Ratio
- CECO $69.85
- ANAB N/A
- Revenue Growth
- CECO 8.97
- ANAB 282.17
- 52 Week Low
- CECO $18.50
- ANAB $12.21
- 52 Week High
- CECO $35.16
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- CECO 24.35
- ANAB 55.28
- Support Level
- CECO $23.76
- ANAB $12.21
- Resistance Level
- CECO $26.08
- ANAB $21.57
- Average True Range (ATR)
- CECO 1.08
- ANAB 1.72
- MACD
- CECO -0.36
- ANAB 0.39
- Stochastic Oscillator
- CECO 0.33
- ANAB 68.16
About CECO CECO Environmental Corp.
CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).